Tune Therapeutics
epigenetic editing, genetic tuning, TEMPO
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
epigenetic editing, genetic tuning, TEMPO
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Tune Therapeutics epigenetic editing, genetic tuning, TEMPO
Tune Therapeutics was founded on advances in gene regulation and describes its technology as enabling control over gene activity. Its proprietary TEMPO platform is intended to dial gene expression up or down without cutting or altering DNA. The company says this approach could address rare genetic disorders as well as common, chronic, and age-related diseases.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Tune Therapeutics — Translational · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic